Trial Profile

A retrospective cohort study assessing the efficacy and safety of Regdanvimab in patients with mild to moderate COVID-19 infections

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Regdanvimab (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use

Most Recent Events

11 Apr 2022 New trial record
04 Apr 2022 Primary endpoint (In-hospital death or disease aggravation which means the need for oxygen therapy) has been met as per the results published in the Journal of Korean Medical Science
04 Apr 2022 Results published in the Journal of Korean Medical Science

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com